Price History

Hover for the daily close. The dotted line marks the period open.

Compare MGRX with… →

MGRX Key Statistics

As of Sep 4, 2026

Trading

Open: $0.39
Previous Close: $0.39
Day's Range: 0.38–0.42
52-Week Range: 0.16–2.75
Volume: 519.70K

Valuation

Market Cap: $8.86M
P/E Ratio: unprofitable
P/S ratio: 28.12
EPS (ttm): −1.06

Financials (FY)

Revenue (FY): $456.02K−25.96%
Net Income (FY): −$20.64M
Profit margin: 0.00%
Shares Outstanding: 21.57M
1-Year Return: −81.49%

Dividend and dates

Avg Volume: 13.78M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MGRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−93.08%−41.76%−69.42%−44.46%

2023*202420252026*

Year	Return
2026 (partial year)	−44.46%
2025	−69.42%
2024	−41.76%
2023 (partial year)	−93.08%

As of September 4, 2026.

MGRX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$456.02K	−$20.64M	−4526.8%
2024	$615.87K	−$8.71M	−1413.6%
2023	$731.49K	−$9.21M	−1259.4%
2022	$8.94K	−$2.00M	−22352.1%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$456.02K	$250.39K	−$19.15M	−$20.64M	−4526.8%
2024	$615.87K	$379.96K	−$8.69M	−$8.71M	−1413.6%
2023	$731.49K	$431.50K	−$9.22M	−$9.21M	−1259.4%
2022	$8.94K	$4.85K	−$1.99M	−$2.00M	−22352.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MGRX Valuation vs Health Information Services Median

Median of 53 stocks

Metric	MGRX	Health Information Services median	vs median
P/S ratio	28.12	2.66	10.6x the median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 53 Health Information Services stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Mangoceuticals, Inc. (MGRX) at $8.86M. The company sits in the Healthcare sector, in the Health Information Services industry. The company reports 3 employees.

MGRX last closed at $0.41 on September 4, 2026. That is +$0.02 (+5.38%) against the previous close. The 52-week range on file runs from $0.16 to $2.75. The latest close sits 153.7% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $456.02K. Against the prior fiscal year total of $615.87K, that is a change of −25.96%. The same year closed with a net loss of $20.64M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.06.

Across the 4 fiscal years on file, revenue moves from $8.94K in 2022 to $456.02K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 28.12. On price-to-sales that is 10.6 times the Health Information Services median of 2.66. 53 Health Information Services companies report these metrics, and the medians quoted come from that group.

Annualized volatility over the trailing 3 years is 169.28%. Over the trailing twelve months the price has returned −81.49%. Measured over 3 years, that is −71.31% a year compounded.

Growth & Income

The record shows no dividend for MGRX.

2026 is still running; the price is −44.46% year to date. The strongest complete calendar year on file is 2024 at −41.76%; the weakest is 2025 at −69.42%.

Peer Comparison

Mangoceuticals, Inc. (MGRX) operates in the Health Information Services industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Mangoceuticals, Inc.	MGRX	$8.86M	—
Veeva Systems Inc.	VEEV	$44.54B	45.0
BrightSpring Health Services, Inc.	BTSG	$12.02B	54.7
Tempus AI, Inc.	TEM	$11.66B	—

The Health Information Services industry average P/E ratio is 41.1x. Mangoceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Health Information Services Stocks

VEEV

Veeva Systems Inc.

$44.54B

BTSG

BrightSpring Health Services, Inc.

$12.02B

TEM

Tempus AI, Inc.

$11.66B

HQY

HealthEquity, Inc.

$7.95B

HNGE

Hinge Health, Inc.

$7.45B

WAY

Waystar Holding Corp.

$4.81B

View all Health Information Services stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Mangoceuticals, Inc.

Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. In addition, the company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.

Visit website →

Mangoceuticals, Inc. (MGRX) Stock Analysis